NCT06709495 2026-02-19Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory SarcomasDana-Farber Cancer InstitutePhase 1/2 Recruiting63 enrolled